Journal: Current Pharmaceutical Biotechnology

Article Title: Evaluation of Changes in the Expression Pattern of EDIL3 in Different Grades of Endometrial Cancer

doi: 10.2174/1389201020666190408112822

Figure Lengend Snippet: Optical density of the reaction product for EDIL3 in different grades of endometrial cancer and control.

Article Snippet: Rabbit polyclonal anti-EDIL3 antibody (Novus Biological, USA) was used to perform immunohistochemical staining of the prepared slides.

Techniques: Control

Journal: Journal of Bone Oncology

Article Title: Tumor derived EDIL3 modulates the expansion and osteoclastogenesis of myeloid derived suppressor cells in murine breast cancer model

doi: 10.1016/j.jbo.2019.100238

Figure Lengend Snippet: Tumor derived EDIL3 inhibits MDSCs expansion in vivo. Nude mice were injected with MDA-MB-231 shEDIL3 cells or MDA-MB-231 shRNA control cells via intracardiac route. Normal MDA-MB-231 cells were set to be control. (A) BM cells were isolated and CD11b + /Gr1 + cells were analysed by flow cytometry. (B) Quantitative analysis of the expansion of CD11b + /Gr1 + cells in bone marrow of tumor bearing mice one month after tumor cells inoculation. All data are means ± SD (5 mice per group).

Article Snippet: The primary antibodies used here are EDIL3 (Ag3274, 1:3000; Proteintech Group, Inc., Chicago, IL, USA) and GAPDH (2118, 1:1000; Cell Signalling Technology, Beverly, MA, USA).

Techniques: Derivative Assay, In Vivo, Injection, shRNA, Control, Isolation, Flow Cytometry

Journal: Journal of Bone Oncology

Article Title: Tumor derived EDIL3 modulates the expansion and osteoclastogenesis of myeloid derived suppressor cells in murine breast cancer model

doi: 10.1016/j.jbo.2019.100238

Figure Lengend Snippet: The effect of EDIL3 on MDSCs generation from BM cells in vitro. (A) BM cells were cultured in medium supplemented with GM-CSF+IL-6 in the presence of recombinant EDIL3 or not for 4 days and then were analysed by flow cytometry. Only image of r-EDIL3 = 0.5 µg/ml was shown here for compare. (B) Quantitative analysis of CD11b + /Gr1 + cells. All data are means ± SD ( n = 6).

Article Snippet: The primary antibodies used here are EDIL3 (Ag3274, 1:3000; Proteintech Group, Inc., Chicago, IL, USA) and GAPDH (2118, 1:1000; Cell Signalling Technology, Beverly, MA, USA).

Techniques: In Vitro, Cell Culture, Recombinant, Flow Cytometry

Journal: Journal of Bone Oncology

Article Title: Tumor derived EDIL3 modulates the expansion and osteoclastogenesis of myeloid derived suppressor cells in murine breast cancer model

doi: 10.1016/j.jbo.2019.100238

Figure Lengend Snippet: EDIL3 dose-dependently inhibits osteoclastogenesis of MDSCs. (A) TRAP staining were performed. TRAP-positive cells as well as area of Trap-positive osteoclasts per field were counted. (B) Osteoclasts were harvested for mRNA expression of the osteoclast-specific genes by quantitative PCR. Results were normalized to those of β-actin mRNA and are presented relative to those of undifferentiated control. All data are means ± SD ( n = 3).

Article Snippet: The primary antibodies used here are EDIL3 (Ag3274, 1:3000; Proteintech Group, Inc., Chicago, IL, USA) and GAPDH (2118, 1:1000; Cell Signalling Technology, Beverly, MA, USA).

Techniques: Staining, Expressing, Real-time Polymerase Chain Reaction, Control

Journal: Journal of Bone Oncology

Article Title: Tumor derived EDIL3 modulates the expansion and osteoclastogenesis of myeloid derived suppressor cells in murine breast cancer model

doi: 10.1016/j.jbo.2019.100238

Figure Lengend Snippet: EDIL3 regulates expression of Nfatc1 and Bcl6 via binding to Mac-1. Effect of r-EDIL3 (2 µg/ml) on Nfatc1 (A) and Bcl6 (B) mRNA expression during osteoclastogenesis of MDSCs which were pre-treated with antibody against CD11b or CD11a. Bcl6 and Nfatc1 expression was determined at 24 and 12 h, respectively. Data were normalized to β-actin mRNA and are relative to undifferentiated controls. All data are means ± SD ( n = 5).

Article Snippet: The primary antibodies used here are EDIL3 (Ag3274, 1:3000; Proteintech Group, Inc., Chicago, IL, USA) and GAPDH (2118, 1:1000; Cell Signalling Technology, Beverly, MA, USA).

Techniques: Expressing, Binding Assay

Journal: Journal of Bone Oncology

Article Title: Tumor derived EDIL3 modulates the expansion and osteoclastogenesis of myeloid derived suppressor cells in murine breast cancer model

doi: 10.1016/j.jbo.2019.100238

Figure Lengend Snippet: Tumor derived EDIL3 decreases the osteoclast number in tumor bearing mice. (A) Representative images of TRAP staining on bone sections from mice inoculated with shEDIL3 MDA-MB-231 cells or control 4 weeks after sacrifice. Osteoclasts were marked by red arrow. (B) Quantitative analysis of the ratio bone surface/osteoclast number. ( n = 8, two images each mice).

Article Snippet: The primary antibodies used here are EDIL3 (Ag3274, 1:3000; Proteintech Group, Inc., Chicago, IL, USA) and GAPDH (2118, 1:1000; Cell Signalling Technology, Beverly, MA, USA).

Techniques: Derivative Assay, Staining, Control

Journal: Journal of Bone Oncology

Article Title: Tumor derived EDIL3 modulates the expansion and osteoclastogenesis of myeloid derived suppressor cells in murine breast cancer model

doi: 10.1016/j.jbo.2019.100238

Figure Lengend Snippet: Tumor derived EDIL3 increases bone mass. (A) Representative micro-CT images. (B) Bone mass (bone volume/total volume and trabecular thickness) was assessed by micro-CT analysis of left tibias from both groups. Data are presented as the mean ± SD. ( n = 8, one image each mice).

Article Snippet: The primary antibodies used here are EDIL3 (Ag3274, 1:3000; Proteintech Group, Inc., Chicago, IL, USA) and GAPDH (2118, 1:1000; Cell Signalling Technology, Beverly, MA, USA).

Techniques: Derivative Assay, Micro-CT